echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > NEJM: Analysis of the effect of dupiluzumab in the treatment of uncontrolled children with moderate to severe asthma

    NEJM: Analysis of the effect of dupiluzumab in the treatment of uncontrolled children with moderate to severe asthma

    • Last Update: 2021-12-25
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Despite the accepted standard of care, suffering from moderate to severe asthma in children will still be complications of the disease
    .


    The monoclonal antibody dupiluzumab has been approved for the treatment of adults and adolescents with asthma and other type 2 inflammatory diseases


    child

    Recently, a research article was published in the top medical journal NEJM.
    In this 52-week randomized, double-blind, placebo-controlled phase 3 trial, researchers assigned 408 uncontrolled patients aged 6 to 11 Of children with moderate to severe asthma receive subcutaneous injections of dupirumumab every 2 weeks (100 mg for patients with a body weight of ≤ 30 kg and 200 mg for patients with a body weight of> 30 kg) or a matching placebo
    .


    All children continue to receive a stable dose of standard background therapy


    The primary endpoint of the study is the annualized rate of severe asthma attacks.
    The secondary endpoints include the predicted percentage of forced expiratory volume in 1 second before bronchodilator (ppFEV1) at week 12 relative to baseline and the Asthma Control Questionnaire 7 interview at week 24 The change in the score of the actor management (ACQ-7-IA)
    .


    Have a type 2 inflammatory asthma phenotype (eosinophils ≥150/mm3 or exhaled nitric oxide fraction at baseline ≥20ppb) or an eosinophil count of at least 300/mm3 at baseline


    manage

    Among patients with type 2 inflammatory phenotypes, the annualized rate of severe asthma attacks in the dupiluzumab group was 0.
    31 (95% confidence interval [CI] 0.
    22 to 0.
    42), and the placebo group was 0.
    75 (95% CI 0.
    54 to 1.
    03) (relative risk reduction in the dupilumab group was 59.
    3%; 95% CI was 39.
    5 to 72.
    6; P<0.
    001)
    .


    The mean (±SE) change in ppFEV1 from baseline was 10.


    It can be seen that among children with uncontrolled moderate to severe asthma, children who received dupilumab had fewer asthma attacks and better lung function and asthma control compared with children who received placebo
    .

    Among children with uncontrolled moderate to severe asthma, children who received dupilumab had fewer asthma attacks and better lung function and asthma control than children who received placebo
    .


    Original source:
     
    Leonard B.


    Bacharier, et al.
    Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma .



    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.